Comparison of the antibacterial effects of nanosilver with 18 antibiotics on multidrug resistance clinical isolates of Acinetobacter baumannii

Jundishapur Journal of Microbiology

Volumn 6, Issue 5, 2013, Pages

  Niakan, Sarah ^a   Niakan, Mohammad ^b   Hesaraki, Saeed ^a   Nejadmoghaddam, Mohammad Reza ^c   Moradi, Mohammad ^b   Hanafiabdar, Mojtaba ^b   Allamezadeh, Roya ^b   Sabouri, Meysam ^c  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acinetobacter baumannii; Antibacterial; Emotions; MBC

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; COTRIMOXAZOLE; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SILVER NANOPARTICLE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DISK DIFFUSION; IRAN; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PARTICLE SIZE;

ACINETOBACTER BAUMANNII; BACILLI (CLASS); NEGIBACTERIA;

EID: 84880799214     PISSN: 20083645     EISSN: 20084161     Source Type: Journal    
DOI: 10.5812/jjm.8341     Document Type: Article

References (28)

1. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9(2):148-165.
2. Koneman EW, Allen DS, Janda M, Schreckenberger CP, Winn CW. Color atlas and textbook of diagnostic microbiology. Acinetobacter. Philadelphia: JB Lippincott Company; 1992. p. 213-215.
3. Jung JY, Park MS, Kim SE, Park BH, Son JY, Kim EY, et al. Risk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unit. BMC Infect Dis. 2010;10:228.
4. Rahbar M, Hajia M. Detection and quantitation of the etiologic agents of ventilator-associated pneumonia in endotracheal tube aspirates from patients in Iran. Infect Control Hosp Epidemiol. 2006;27(8):884-885.
5. Chen D, Xi T, Bai J. Biological effects induced by nanosilver particles: in vivo study. Biomed Mater. 2007;2(3):S126-S128.
6. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, et al. Antimicrobial effects of silver nanoparticles. Nanomedicine. 2007;3(1):95-101.
7. El-Ansary A, Al-Daihan S. On the toxicity of therapeutically used nanoparticles: an overview. J Toxicol. 2009;2009.
8. Moeller K. Nano-Silver Proven Safe for Humans, American Biotech Labs. 2009; Available from: http://www.healthfreedomusa.org.
9. Panyala Nagender Reddy, Peña-Méndez Eladia María, Havel Josef. Silver or silver nanoparticles: a hazardous threat to the environment and human health. J. Appl. Biomed. 2008;6(3):117-129.
10. Constantiniu Sofa, Romaniuc Angela, Iancu Luminiţa Sma-randa, Filimon Raluca, Taraşi Iuliana. Cultural and biochemical characteristics of Acinetobacter spp. Strains isolated from hospital units. J Prevent Med. 2004;12:35-42.
11. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement; M100-S20. 2010; Available from: http://www.idsociety.org/Antimicrobial_Susceptibil-ity_Testing/.
12. Abbasi F, Yadegarynia D, Mardani M, Frasinejad B, Yaghubi T, Gholamin S. Emerging multi drug-resistant Acinetobacter in Iran: Study of 800 cases. Int J Infect Dis. 2010;14:e36
13. Vahdani Parviz, Yaghoubi Tofgh, Aminzadeh Zohreh. Hospital acquired antibiotic-resistant Acinetobacter baumannii infections in a 400-bed hospital in Tehran, Iran. Int J Prevent Med. 2011;2(3):127.
14. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother. 2002;49(3):479-487.
15. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000;31(1):101-106.
16. Medic D, Ukropina MM, Gusman V, Jelesic Z, Milosavljevic B. Car-bapenems resistance of Acinetobacter spp strains isolated from wound swabs during 2009-2010. Med Pregl. 2011;64(11-12):583-587.
17. Gaur A, Garg A, Prakash P, Anupurba S, Mohapatra TM. Observations on carbapenem resistance by minimum inhibitory concentration in nosocomial isolates of Acinetobacter species: an experience at a tertiary care hospital in North India. J Health Popul Nutr. 2008;26(2):183-188.
18. Dhabaan Gh N, Hamimah H, Shorman MA. Emergence of extensive drug-resistant Acinetobacter baumannii in North of Jordan. African J Microbiol Res. 2011;5(9):1070-5.
19. Moniri R, Farahani RK, Shajari G, Shirazi MN, Ghasemi A. Molecular epidemiology of aminoglycosides resistance in acineto-bacter spp. With emergence of multidrug-resistant strains. Iran J Public Health. 2010;39(2):63-68.
20. Baker C, Pradhan A, Pakstis L, Pochan Darrin J, Shah S Ismat. Synthesis and antibacterial properties of silver nanoparticles. J Na-nanotechnol. 2005;5(2):244-249.
21. Mrones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT, et al. The bactericidal efect of silver nanoparticles. Nanotechnology. 2005;16(10):2346-2353.
22. Panácek Aleš, Kvitek Libor, Prucek Robert, Kolar Milan, Vecerova Renata, Pizurova Nadezda, et al. Silver colloid nanoparticles: synthesis, characterization, and their antibacterial activity. J Phys Chem B. 2006;110(33):16248-16253.
23. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherich-coli. Nanomedicine. 2007;3(2):168-171.
24. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci. 2004;275(1):177-182.
25. Hatchett David W, White Henry S. Electrochemistry of Sulfur Adlayers on the Low-Index Faces of Silver. J Phys Chem. 1996;100(23):9854-9859.
26. Lara Humberto H, Ayala-Núnez Nilda V, Ixtepan Turrent, Liliana del Carmen, Rodríguez Padilla Cristina. Bactericidal efect of silver nanoparticles against multidrug-resistant bacteria. World J Microbiol Biotechnol. 2010;26(4):615-621.
27. Amany A, El-Rab Sanaa F Gad. Effect of reducing and protecting agents on size of silver nanoparticles and their anti-bacterial activity. Der Pharma Chemica, 2012;4(1):53-65.
28. Petrus EM, Tinakumari S, Chai LC, Ubong A, Tunung R, Elexson N, et al. A study on the minimum inhibitory concentration and minimum bactericidal concentration of Nano Colloidal Silver on food-borne pathogens. Int Food Res J. 2011;18:55-66.